Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SELIM R BENBADIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1710902689
CMS profile
258738
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$311,991.58

541 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
EISAI INC. $127,263.74 213
Greenwich Biosciences, Inc. $77,416.46 120
Sunovion Pharmaceuticals Inc. $63,460.36 87
LivaNova USA, Inc. $39,656.07 90
Biogen, Inc. $1,395.63 2
Ceribell, Inc. $1,333.33 1
Medtronic USA, Inc. $1,138.42 13
NeuroPace, Inc. $327.57 15

Page 11 of 11; records 501–541 of 541 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SELIM R BENBADIS

NPI 1710902689 · CMS profile ID 258738

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 11 of 11; records 501–541 of 541 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710902689?year=2019&recipient=provider&page=11#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SELIM R BENBADIS, NPI 1710902689, CMS profile ID 258738. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 11; records 501–541 of 541 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710902689?year=2019&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SELIM R BENBADIS, NPI 1710902689, CMS profile ID 258738. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 11 of 11; records 501–541 of 541 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710902689?year=2019&recipient=provider&page=11#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SELIM R BENBADIS, NPI 1710902689, CMS profile ID 258738, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 11 of 11; records 501–541 of 541 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1710902689?year=2019&recipient=provider&page=11#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

541 matching records · $311,991.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 541 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 501–541 of 541.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EISAI INC. $107.4002/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697038925 CMS
Eisai Inc. $20.0002/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701430151 CMS
Greenwich Biosciences, Inc. $65.6302/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802465 CMS
EISAI INC. $276.2502/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696991709 CMS
EISAI INC. $18.3802/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696999221 CMS
EISAI INC. $2,900.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697038823 CMS
Greenwich Biosciences, Inc. $2,100.0001/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802495 CMS
Greenwich Biosciences, Inc. $235.4701/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802581 CMS
Greenwich Biosciences, Inc. $100.5301/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802697 CMS
Greenwich Biosciences, Inc. $73.0001/31/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802843 CMS
Greenwich Biosciences, Inc. $22.7401/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701803035 CMS
LivaNova USA, Inc. $12.5501/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456041 CMS
Greenwich Biosciences, Inc. $66.9601/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802469 CMS
LivaNova USA, Inc. $140.8901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456011 CMS
Greenwich Biosciences, Inc. $2,700.0001/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802491 CMS
Greenwich Biosciences, Inc. $160.8801/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802577 CMS
Greenwich Biosciences, Inc. $132.5001/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802647 CMS
Greenwich Biosciences, Inc. $25.0001/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802693 CMS
Greenwich Biosciences, Inc. $25.0001/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802771 CMS
Greenwich Biosciences, Inc. $85.0001/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802839 CMS
LivaNova USA, Inc. $2,350.0001/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456021 CMS
EISAI INC. $83.8301/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696996671 CMS
EISAI INC. $2,900.0001/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696996673 CMS
EISAI INC. $20.0001/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696996675 CMS
EISAI INC. $156.6001/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696996677 CMS
EISAI INC. $6.0001/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696996679 CMS
EISAI INC. $14.0001/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696996681 CMS
EISAI INC. $194.0101/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697041165 CMS
Ceribell, Inc. $1,333.3301/13/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699909097 CMS
LivaNova USA, Inc. $55.4501/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456007 CMS
LivaNova USA, Inc. $21.6801/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456005 CMS
LivaNova USA, Inc. $213.5701/11/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456311 CMS
LivaNova USA, Inc. $202.0701/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456313 CMS
Greenwich Biosciences, Inc. $3,200.0001/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802485 CMS
Greenwich Biosciences, Inc. $331.8901/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802573 CMS
Greenwich Biosciences, Inc. $120.5601/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802643 CMS
Greenwich Biosciences, Inc. $20.0001/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802689 CMS
Greenwich Biosciences, Inc. $25.0001/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802767 CMS
Greenwich Biosciences, Inc. $190.0001/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701802835 CMS
LivaNova USA, Inc. $21.4101/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456013 CMS
LivaNova USA, Inc. $26.1601/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703456037 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $311,991.58 541
PY2020 $166,691.19 233
PY2021 $310,804.15 408
PY2022 $327,613.75 448
PY2023 $318,151.45 460
PY2024 $334,322.16 486
PY2025 $322,649.03 485

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $118,980.86 47
PY2024 Principal investigator $87,865.69 52
PY2023 Principal investigator $242,936.44 49
PY2022 Principal investigator $98,253.40 16
PY2021 Principal investigator $63,369.44 11
PY2020 Principal investigator $201,909.00 31
PY2019 Principal investigator $197,376.25 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SK Life Science, Inc. $2,411.50 12/31/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274913
Principal investigator 1 SK Life Science, Inc. $5,185.70 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274983
Principal investigator 1 SK Life Science, Inc. $716.30 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274985
Principal investigator 1 SK Life Science, Inc. $716.30 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274987
Principal investigator 1 SK Life Science, Inc. $650.00 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274989
Principal investigator 1 UCB SA $300.00 12/10/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246656826
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,091.53 12/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORID
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223289376
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,810.12 12/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORID
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223289386
Principal investigator 1 SK Life Science, Inc. $5,645.90 12/03/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274981
Principal investigator 1 SK Life Science, Inc. $3,035.80 11/27/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274977
Principal investigator 1 SK Life Science, Inc. $166.67 11/27/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274979
Principal investigator 1 UCB SA $27.89 11/25/2025 Non-covered Recipient Entity
Usf Health South Tampa Center For Advanced Healthcare
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246659324
Principal investigator 1 SK Life Science, Inc. $2,674.10 11/21/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274975
Principal investigator 1 SK Life Science, Inc. $1,092.00 11/20/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274973
Principal investigator 1 ABBVIE INC. $4,513.86 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202518469
Principal investigator 1 ABBVIE INC. $1,920.39 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202518471
Principal investigator 1 H. Lundbeck A S $3,300.00 10/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251775619
Principal investigator 1 SK Life Science, Inc. $3,150.00 09/19/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274971
Principal investigator 1 ABBVIE INC. $3,757.50 09/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202510810
Principal investigator 1 H. Lundbeck A S $4,750.00 09/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251774385
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223284765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223284767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223284769
Principal investigator 1 H. Lundbeck A S $12,850.00 08/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251773900
Principal investigator 1 H. Lundbeck A S $2,500.00 08/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251773905
Principal investigator 1 SK Life Science, Inc. $650.00 08/18/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274925
Principal investigator 1 SK Life Science, Inc. $900.00 06/26/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 06/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223281178
Principal investigator 1 SK Life Science, Inc. $650.00 05/28/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274933
Principal investigator 1 ABBVIE INC. $1,000.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202485999
Principal investigator 1 ABBVIE INC. $3,666.67 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202486001
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,290.69 05/21/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution No dispute reported 06/30/2026 1233745578
Principal investigator 1 SK Life Science, Inc. $2,200.00 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274935
Principal investigator 1 SK Life Science, Inc. $4,891.90 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274937
Principal investigator 1 SK Life Science, Inc. $811.20 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274939
Principal investigator 1 SK Life Science, Inc. $2,200.00 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274941
Principal investigator 1 SK Life Science, Inc. $4,891.90 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274915
Principal investigator 1 SK Life Science, Inc. $1,000.00 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274917
Principal investigator 1 SK Life Science, Inc. $468.00 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274919
Principal investigator 1 SK Life Science, Inc. $650.00 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274921
Principal investigator 1 SK Life Science, Inc. $1,090.80 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274923
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 04/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223277646
Principal investigator 1 UCB SA $1,200.00 03/21/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures No dispute reported 06/30/2026 1246656396
Principal investigator 1 ABBVIE INC. $4,270.00 02/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202455041
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,887.04 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution No dispute reported 06/30/2026 1233745580
Principal investigator 1 SK Life Science, Inc. $2,247.10 01/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274927
Principal investigator 1 SK Life Science, Inc. $5,100.00 01/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274929